Rebooting the BTK Inhibitor Sequence in MCL
Co-Chairs, Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD, and Nirav Shah, MD, MS, discuss mantle cell lymphoma in this CME/MOC/NCPD/CPE/IPCE activity titled “Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease.” For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/IPCE information, and to apply for credit, please visit us at PeerView.com/FHV865. CME/MOC/NCPD/CPE/IPCE credit will be available until October 1, 2023.
Rebooting the BTK Inhibitor Sequence in MCL
Теги
CMEMOCNCPDCPEIPCEmededoncologyhematologyBTK inhibitorsmantle cell lymphomaMCLR/R MCLcovalent BTK inhibitorsnoncovalent BTK inhibitorsacalabrutinibibrutinibzanubrutinibpirtobrutinibSHINECAR-TZUMA-2brexucabtagene autoleucelBRUINBRUIN MCL-321lenalidomideBTKi selectivityBTKi resistanceDr Toby A Eyre MBChB DipMedEd MRCP FRCPath MDNirav Shah MD MS
